Analysts Eye Major Upside Targets

 StocksRunner
 
  StocksRunner
 
Follow  Message
 
 
 
Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends
 

•  23 Sep 2025
 

•   ALC  
   
  -0.31%
•   AVGO  
   
  +0.16%
•   CRWD  
   
  -1.54%
•   MBX  
   
  +4.96%
•   PATH  
   
  -1.84%

$ALC Alico Inc presents an intriguing opportunity with analysts projecting a massive 325% upside potential, targeting $319.60 from its current $75.20 price level. However, technical indicators paint a concerning picture with the stock in a clear downtrend and RSI at a low 33.06, suggesting oversold conditions. The trading volume of 2.92M exceeds its average of 2.31M, indicating increased interest, but investors should be cautious given the negative momentum. The wide gap between current price and 200-day moving average at $87.61 signals significant technical headwinds that could persist in the near term.

$CRWD CrowdStrike commands attention with its dominant Falcon cybersecurity platform and identical 325% analyst upside target, aiming for $2,057.43 from $484.10. The company's all-in-one cybersecurity solution positions it well in the growing AI security market. Despite recent challenges, the stock shows neutral momentum with RSI at 65.02 and trades above key moving averages. However, current volume at 2.13M trails the 3.58M average, suggesting reduced conviction. The massive market cap of $121.49B and premium valuation require strong execution to justify analyst optimism.

$AVGO Broadcom emerges as a compelling AI infrastructure play with analysts targeting 100% upside to $677.88 from $338.94. The company's AI chip revenue surge of 63% year-over-year demonstrates real momentum in this critical sector. Technical indicators support the bullish case with an uptrend classification and RSI at 55.74, suggesting room for further gains. Trading above all major moving averages reinforces positive momentum, though current volume of 20.87M falls short of the 26.15M average. The $1.60T market cap reflects its established position in the semiconductor ecosystem.

$MBX Biosciences shows strong analyst confidence with an 88.55% upside target to $35.75 from $18.96. The biotech sector offers high-risk, high-reward potential, and the significantly elevated volume of 2.74M versus 1.34M average suggests growing institutional interest. However, the negative EPS of -3.3 and early-stage nature typical of biotech companies require careful risk assessment. The RSI at 62.84 indicates neutral momentum, while the small $636.94M market cap provides room for substantial moves in either direction.

$PATH UiPath presents a modest opportunity with just 3.43% upside to $12.96 from $12.53, having recently crossed above analyst targets. The robotic process automation leader benefits from the broader AI adoption trend, but the minimal upside suggests limited near-term catalysts. Volume of 16.06M exceeds the 12.50M average, indicating active trading interest. The high PE ratio of 343.48 suggests premium valuation that may limit further appreciation until fundamental improvements materialize.

View All Headlines